Home・Akcijų sąrašas・MacroGenics Inc

MacroGenics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

4.23 3.42

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.7800000000000002

Max

4.23

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-23M -37M
Pardavimai	-20M 21M
Pelnas, tenkantis vienai akcijai	-0.58
Pelno marža	-177.011
Darbuotojai	293
EBITDA	-15M -30M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+59.31% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-19

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	72M 259M
Ankstesnė atidarymo kaina	0.81
Ankstesnė uždarymo kaina	4.23

Naujienos nuotaikos

By Acuity

28%

72%

100 / 340 reitingas Healthcare

MacroGenics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-14 19:21; UTC

Shares of MacroGenics Inc. are lower today amid cautious investor sentiment following a drop in U.S. retail sales, impacting expectations for Federal Reserve interest rate hikes.

2026-08-13 21:01; UTC

News

MacroGenics shares declined after reporting Q2 2026 results, which included a workforce reduction and a pro forma cash position of $327 million.

2026-08-12 19:46; UTC

Social Media

MacroGenics Inc received a $10 million milestone payment, boosting investor sentiment and contributing to shares trading higher during Wednesday's session.

2026-08-11 22:26; UTC

News

MacroGenics shares rise after Gilead Sciences exercises licensing option, triggering a $10 million payment and potential for $1.6 billion in future milestones.

2026-08-04 19:46; UTC

MacroGenics shares are lower today, retracing from a session high amid a broader market decline linked to falling crude oil prices.

2026-07-31 20:06; UTC

MacroGenics Inc. shares are lower today amid rising U.S. Treasury yields and inflation concerns, continuing a downward trend since Thursday's close.

2026-07-29 20:09; UTC

MacroGenics Inc shares are lower today, continuing a downward trend since Tuesday's close. The stock showed early gains before sharply reversing course.

2026-07-28 17:03; UTC

MacroGenics Inc shares are lower today amid broader market volatility. The stock remains near the lower end of its one-month range.

2026-07-27 20:01; UTC

News

MacroGenics shares are higher as analysts remain optimistic about MGC026's potential, supported by a strong cash runway projected until 2028.

2026-07-24 20:01; UTC

MacroGenics Inc shares are declining amid broader biotechnology sector weakness, marking four consecutive sessions of losses with no specific company news identified.

2026-07-22 19:51; UTC

MacroGenics Inc is trading lower today, breaking a trend of higher closes. Broader market sentiment is cautious amid rising crude oil prices and geopolitical tensions.

2026-07-21 19:06; UTC

MacroGenics Inc shares are higher, supported by optimism in the semiconductor sector and potential price increases from TSMC by 2027.

Akcijų palyginimas

Kainos pokytis

MacroGenics Inc Prognozė

Kainos tikslas

By TipRanks

59.31% į viršų

12 mėnesių prognozė

Vidutinis 6.5 USD 59.31%

Aukščiausias 9 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MacroGenics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių MacroGenics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

100 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.